![John Miller](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
John Miller
Corporate Officer/Principal presso JAZZ PHARMACEUTICALS PLC
Posizioni attive di John Miller
Società | Posizione | Inizio | Fine |
---|---|---|---|
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 01/02/2015 | - |
Storia della carriera di John Miller
Precedenti posizioni note di John Miller
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2012 | 01/08/2012 |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/02/2011 | 01/02/2012 |
Formazione di John Miller
University of Mississippi | Undergraduate Degree |
Questrom School of Business | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Irlanda | 2 |
Canada | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
JAZZ PHARMACEUTICALS PLC | Health Technology |
Aziende private | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Borsa valori
- Insiders
- John Miller
- Esperienza